Tuning up CAR t: can a better prep boost lymphoma remission?

NCT ID NCT05950802

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for adults with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to treatment. Researchers want to find the safest and most effective way to prepare the body before giving standard CAR T cell therapy. They are testing different doses of chemotherapy, with or without low-dose radiation, to see if this improves how well the treatment works. The goal is to control the disease and achieve remission, not to provide a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma interdigitating dendritic cell sarcoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL - DIFFUSE LARGE B CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••